Journal
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
Volume 34, Issue 7, Pages 524-527Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MPH.0b013e31826b9d25
Keywords
sarcoma; gemcitabine; docetaxel; bevacizumab
Categories
Ask authors/readers for more resources
Background: The outcome for patients with relapsed and refractory pediatric sarcomas remains dismal. Novel agents are needed to improve overall survival in these patients. Observations: We present 3 patients with relapsed/refractory sarcomas treated with gemcitabine, docetaxel, and bevacizumab in 3-week cycles. The combination was well tolerated with minimal toxicity. Two patients had a partial response and the third patient had stable disease for >6 months. Conclusions: These results are limited by small patient numbers but this strategy should be evaluated in prospective clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available